Hormonal

Omitting initial glucose-lowering drug treatment (GLDT) in newly diagnosed type 2 diabetes is associated with a higher 5-year risk of major adverse cardiovascular events (MACE), primarily mediated by lower initiation of statins and renin-angiotensin system inhibitors (RASi), even in patients achieving glycemic remission.

If you have newly diagnosed type 2 diabetes, even if you manage to normalize your blood sugar through diet and exercise (remission), you may still be at higher risk for heart attacks or strokes if you avoid glucose-lowering drugs. This is likely because avoiding these drugs also means you are less likely to be prescribed essential heart-protective medications like statins or blood pressure drugs. Ensure your doctor prescribes appropriate cardiovascular prevention strategies regardless of your glycemic status.